Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 20/20 | 1.00 |
| ▸ | APOBEC3G | Q9HC16 | 5/20 | 0.55 |
| ▸ | GAA | P10253 | 3/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24324351 | 0.93 | PLK1 (0.87) | PLK1APOBEC3GGAANPC1 | |
| SCHEMBL26851614 | 0.90 | PLK1 (0.87) | PLK1APOBEC3GGAANPC1 | |
| SCHEMBL24324406 | 0.87 | PLK1 (1.00) | PLK1APOBEC3GGAANPC1 | |
| SCHEMBL29446335 | 0.87 | PLK1 (1.00) | PLK1APOBEC3GGAANPC1 | |
| SCHEMBL24324352 | 0.85 | PLK1 (0.76) | PLK1APOBEC3GGAANPC1 | |
| SCHEMBL29446346 | 0.85 | PLK1 (0.76) | PLK1APOBEC3GGAANPC1 | |
| SCHEMBL26851689 | 0.85 | PLK1 (0.76) | PLK1APOBEC3GGAANPC1 | |
| SCHEMBL29446416 | 0.85 | PLK1 (0.83) | PLK1APOBEC3GGAANPC1 | |
| SCHEMBL26851703 | 0.85 | PLK1 (0.83) | PLK1APOBEC3GGAANPC1 | |
| SCHEMBL29446341 | 0.84 | PLK1 (1.00) | PLK1APOBEC3G |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365568-A1 | PLK1 POLO BOX DOMAIN INHIBITORS AND METHOD OF TREATING CANCER | THE UNITED STATES OF AMERICA,AS REPRESENTED BY THE SECRETARY,DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-11-16 | — | — | US | disclosed |
| US-20230365568-A1 | PLK1 POLO BOX DOMAIN INHIBITORS AND METHOD OF TREATING CANCER | THE UNITED STATES OF AMERICA,AS REPRESENTED BY THE SECRETARY,DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-11-16 | — | — | US | disclosed |
| EP-4216958-A2 | PLK1 POLO BOX DOMAIN INHIBITORS AND METHOD OF TREATING CANCER | The United States of America, as represented by the Secretary, Department of Health and Human Services (US) | 2023-08-02 | — | — | EP | disclosed |
| WO-2022067100-A2 | PLK1 POLO BOX DOMAIN INHIBITOR AND METHOD OF TREATING CANCER | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2022-03-31 | — | — | WO | disclosed |
| WO-2022067100-A2 | PLK1 POLO BOX DOMAIN INHIBITOR AND METHOD OF TREATING CANCER | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2022-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230365568-A1 | PLK1 POLO BOX DOMAIN INHIBITORS AND METHOD OF TREATING CANCER | PLK1, PLK4, BUB1B | PLK1 1/4885APOBEC3G 3281/4885GAA 3466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.